entertainment -WSS

entertainment

author：comprehensive 2025-09-28 21:56:32 - browse：76728

An Ozempic pen connects dots that make up the shape o a brain — coverage from STAT — ILLUSTRATION: CHRISTINE KAO/STAT; PHOTOS: ADOBE

Drugs like Ozempic and Wegovy — already game changers for diabetes and obesity — are being studied to treat an entirely different growing health problem: mental health illnesses, including depression and bipolar disorder.

Early data and anecdotes suggest that this class of GLP-1 drugs could help patients feel less depressed and anxious. The treatment may also fight the decline in cognitive and executive function that many people with mental health disorders experience, like worsening memory and losing the ability to focus and plan.

If further research yields positive results, it could drive even more demand for the highly popular GLP-1 treatments, which have increasingly been shown to help with problems across the body, such as heart and kidney complications. And especially if the cognitive benefits are proven out, the GLP-1 drugs would plug a critical gap in current treatments for depression, since most depression drugs help with mood, but close to none address cognitive symptoms that affect memory and attention.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Why rehabilitation engineers need to center patients in their research

WSS

Obamacare plans could cover weight loss drugs

Close Medicare's dangerous gaps in addiction treatment coverage

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Cancer researcher Catriona Jamieson is sending tumors into space

H5N1 bird flu found in pasteurized milk: what we know

Cancer researcher Catriona Jamieson is sending tumors into space

hotspot

entertainment

focus

Trump demands the U.S. pay no more for drugs than other countries … again

Measles policy set amid Florida outbreak alarms vaccine proponents

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Heart attack and stroke risk calculators need revising

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

23andMe had bad news about my health. I wish a person had delivered it

Researchers tackle phage therapy hurdles for wider adoption

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Obamacare plans could cover weight loss drugs

entertainment

Opioid cravings were reduced by anti

Reporting on presidential health from Reagan to Trump and Biden

Abridge raises $150m as clinical notes automation market heats up

As AI regulations shape up, health tech startups beg for clarity

Cell therapy fails to slow type 1 diabetes, but safety is established

More tobacco lobbyists active in statehouses

focus

hotspot

knowledge

knowledge